DoD tests AI models that make it easy to switch from vendors like Palantir
LAUSANNE, Switzerland - ADC Therapeutics SA (NYSE: ADCT), a biotechnology company with a market capitalization of $350.1 million, reported that its combination therapy of ZYNLONTA with glofitamab demonstrated a 93.3% overall response rate and 86.7% complete response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to updated data from the LOTIS-7 Phase 1b trial. According to InvestingPro data, the company has shown strong market momentum with a 78% return over the past six months, reflecting investor optimism about its clinical developments.
The data, presented at the European Hematology Association 2025 Congress, showed that 25 of 26 patients who achieved complete response remained in that state as of the April 14 data cutoff. Among six patients previously treated with CAR-T therapy, five achieved complete response.
The study evaluated 41 patients for safety and 30 for efficacy across two ZYNLONTA dose levels (120 μg/kg and 150 μg/kg) in combination with glofitamab. The combination demonstrated a manageable safety profile with no dose-limiting toxicities.
The most common grade 3 or higher treatment-emergent adverse events included neutropenia (24.4%), anemia (9.8%), and thrombocytopenia (7.3%). Cytokine release syndrome occurred in 23.8% of patients at the 150 μg/kg dose (all Grade 1) and 55% at the 120 μg/kg dose.
"The combination of these two anti-cancer agents holds significant promise for advancing the treatment landscape and addressing unmet need in patients with these hard-to-treat lymphomas," said Mohamed Zaki, Chief Medical Officer of ADC Therapeutics, according to the press release statement.
Based on these results, the company is expanding enrollment for the LOTIS-7 trial to 100 patients at the 150 μg/kg dose level. Additional data from the study is expected before the end of 2025.
In other recent news, ADC Therapeutics has reported mixed financial results for the fourth quarter of 2024. The company posted an earnings per share (EPS) of -$0.25, surpassing analysts’ expectations of -$0.43, while its revenue of $16.91 million fell short of the anticipated $18.85 million. Despite the revenue miss, the company remains focused on expanding its drug ZYNLONTA’s market presence. Guggenheim Securities recently adjusted its outlook on ADC Therapeutics by lowering the price target to $7 from $10, while maintaining a Buy rating, following the company’s earnings announcement. RBC Capital Markets has maintained its Outperform rating with a price target of $8.00, expressing optimism for ZYNLONTA’s future despite the competitive landscape. ADC Therapeutics is advancing its LOTIS-7 Phase 1b clinical trial, reporting a high overall response rate of 95.5% and a complete response rate of 90.9% in patients with diffuse large B-cell lymphoma. The company plans to release several key data updates throughout 2025, including interim results from the LOTIS-7 study and top-line Phase 3 results from the LOTIS-5 trial. These developments are anticipated to significantly impact the company’s strategic growth and revenue generation efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.